INCB 3284 dimesylate is primarily investigated for its potential therapeutic applications in the field of oncology. It functions as a selective inhibitor targeting specific signaling pathways involved in cancer cell proliferation and survival. Research focuses on its ability to modulate immune responses and inhibit tumor growth, making it a candidate for combination therapies with other anticancer agents. Its application is particularly explored in hematologic malignancies and solid tumors, where it may enhance the efficacy of existing treatments. Clinical trials are ongoing to evaluate its safety, tolerability, and effectiveness in patients, with the aim of developing novel treatment strategies for challenging cancer types.